Agios Pharmaceuticals(AGIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AGIO Agios Pharmaceuticals

Market Closed 06-26 16:00:00 EDT

37.90

+1.70

+4.70%

盘后37.90

+0.000.00%

19:57 EDT

High38.29	Low35.90	Vol3.84M
Open36.36	D1 Closing36.20	Amplitude6.60%
Mkt Cap2.25B	Tradable Cap1.92B	Total Shares59.47M
T/O144.52M	T/O Rate7.58%	Tradable Shares50.62M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AGIO","market":"US","secType":"STK","nameCN":"Agios Pharmaceuticals","latestPrice":37.9,"timestamp":1782504000000,"preClose":36.2,"halted":0,"volume":3836353,"hourTrading":{"tag":"盘后","latestPrice":37.9,"preClose":37.9,"latestTime":"19:57 EDT","volume":918619,"amount":34815387.218567,"timestamp":1782518228192,"change":0,"changeRate":0,"amplitude":0.003958},"delay":0,"changeRate":0.04696132596685071,"floatShares":50618600,"shares":59471609,"eps":-7.255931,"marketStatus":"Market Closed","change":1.7,"latestTime":"06-26 16:00:00 EDT","open":36.36,"high":38.29,"low":35.9,"amount":144520558.22302002,"amplitude":0.066022,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-7.255931,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1782720000000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1374638400000,"exchange":"NASDAQ","adjPreClose":36.2,"preHourTrading":{"tag":"盘前","latestPrice":36.68,"preClose":36.2,"latestTime":"08:29 EDT","volume":8,"amount":295,"timestamp":1782476989009,"change":0.48,"changeRate":0.01326,"amplitude":0.014365},"postHourTrading":{"tag":"盘后","latestPrice":37.9,"preClose":37.9,"latestTime":"19:57 EDT","volume":918619,"amount":34815387.218567,"timestamp":1782518228192,"change":0,"changeRate":0,"amplitude":0.003958},"volumeRatio":3.1108235080141,"impliedVol":0.7147,"impliedVolPercentile":0.7649},"requestUrl":"/m/hq/s/AGIO/tweets","defaultTab":"tweets","newsList":[{"id":"2645308248","title":"Agios Pharmaceuticals (AGIO) Is Up 10.3% After New Mitapivat Phase 3 Data and Share Filing – Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2645308248","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645308248?lang=en_us&edition=fundamental","pubTime":"2026-06-23 22:27","pubTimestamp":1782224856,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals recently filed a US$66.16 million shelf registration for 2,000,000 common shares tied to an employee stock ownership plan and, earlier this month, presented 52-week Phase 3 RISE UP data for mitapivat in sickle cell disease at the European Hematology Association Congress.\nThe newly disclosed analyses showed mitapivat was associated with clinically meaningful reductions in transfusion burden and stronger outcomes among hemoglobin responders, adding important detail beyond...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/agios-pharmaceuticals-agio-is-up-103-after-new-mitapivat-pha","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/agios-pharmaceuticals-agio-is-up-103-after-new-mitapivat-pha","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644117036","title":"Agios Pharmaceuticals shareholders approve 2 million-share increase to 2023 stock incentive plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2644117036","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644117036?lang=en_us&edition=fundamental","pubTime":"2026-06-19 04:14","pubTimestamp":1781813646,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals held its annual stockholder meeting on June 18, 2026.Stockholders backed an amendment to the 2023 Stock Incentive Plan, adding 2 million shares for issuance, including 2 million for incentive stock options.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agios Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDL4GK9Pm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643975341","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2643975341","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643975341?lang=en_us&edition=fundamental","pubTime":"2026-06-16 18:01","pubTimestamp":1781604086,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Agios Pharma (AGIO) and Stevanato Group (STVN) with ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-228?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-228?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","STVN","BK4539","BK4121","AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643034062","title":"Truist Financial Keeps Their Buy Rating on Agios Pharma (AGIO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2643034062","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643034062?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:18","pubTimestamp":1781525918,"startTime":"0","endTime":"0","summary":"In a report released today, Gregory Renza from Truist Financial maintained a Buy rating on Agios Pharma, with a price target of $36.00. According t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/truist-financial-keeps-their-buy-rating-on-agios-pharma-agio-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/truist-financial-keeps-their-buy-rating-on-agios-pharma-agio-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643277414","title":"Agios Pharmaceuticals (AGIO) Is Up 7.4% After Mitapivat RISE UP Data in Sickle Cell Disease - Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2643277414","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643277414?lang=en_us&edition=fundamental","pubTime":"2026-06-15 18:18","pubTimestamp":1781518695,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals recently presented detailed 52-week Phase 3 RISE UP data for its oral PK activator mitapivat in adults with sickle cell disease, showing statistically significant hemoglobin responses and a clinically meaningful reduction in transfusion burden versus placebo.\nAn important nuance for investors is that while pain crises and fatigue endpoints were not statistically different overall, mitapivat hemoglobin responders saw marked improvements in crises, hospitalizations, and...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/agios-pharmaceuticals-agio-is-up-74-after-mitapivat-rise-up","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/agios-pharmaceuticals-agio-is-up-74-after-mitapivat-rise-up","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["RISE","BK4139","UP","AGIO","BK4008"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643272224","title":"Agios Pharmaceuticals price target raised to $54 from $50 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2643272224","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643272224?lang=en_us&edition=fundamental","pubTime":"2026-06-15 18:06","pubTimestamp":1781518010,"startTime":"0","endTime":"0","summary":"H.C. Wainwright raised the firm’s price target on Agios Pharmaceuticals (AGIO) to $54 from $50 and keeps a Buy rating on the shares. The company ov...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/agios-pharmaceuticals-price-target-raised-to-54-from-50-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/agios-pharmaceuticals-price-target-raised-to-54-from-50-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643273065","title":"U.S. RESEARCH ROUNDUP-Ferrari, Hawkeye 360, Micron Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2643273065","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643273065?lang=en_us&edition=fundamental","pubTime":"2026-06-15 15:49","pubTimestamp":1781509797,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Ferrari, Hawkeye 360, Micron TechnologyJune 15 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Fer","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nL4N42N0L1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVNW","DVN","CEVA","DXCM","ESE","QBTX","CASY","CDNL","MUU","EPAM","MU","FSLR","ELF","MULL","ASH","QBTS","QBY","RACE","BDSX","FLYT","BETR","BIIB","AVA","DRI","KMX","FLY","ELTX","ADM","DOGD","AME","CACI","CTAS","ADBE","EXR","MUD","AGIO","CBRE","AXPG","ASMB","CHRW","HAE","DDOG","DT","ACM","ADBG","CROX","CZR","AXP","QBTZ","ARCB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643224964","title":"Agios posts EHA 2026 investor event presentation on rare hematology pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2643224964","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643224964?lang=en_us&edition=fundamental","pubTime":"2026-06-15 12:20","pubTimestamp":1781497223,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals published an EHA 2026 investor event presentation highlighting Phase 3 results for mitapivat in sickle cell disease.RISE UP trial: hemoglobin response 40.6% on mitapivat vs 2.9% on placebo ; response maintained through Week 52.Responders on mitapivat showed a 1.6 g/dL mean increase in average hemoglobin from Week 24 to Week 52.Sickle cell pain crises annualized rate fell 14% vs placebo; p-value 0.1213.Pipeline update: tebapivat Phase 2 data expected in H2; cevidoplenib Phase 3 planned for H1 2028; AG-236 posted positive Phase 1 data.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agios Pharmaceuticals Inc. published the original content used to generate this news brief on June 15, 2026, and is solely responsible f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nNDL6q50F9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643324749","title":"Agios Pharmaceuticals presented results from Phase 3 trial of mitapivat","url":"https://stock-news.laohu8.com/highlight/detail?id=2643324749","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643324749?lang=en_us&edition=fundamental","pubTime":"2026-06-15 04:35","pubTimestamp":1781469305,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals (AGIO) presented detailed results from the 52-week double-blind period of the global RISE UP Phase 3 trial of mitapivat. Thes...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/agios-pharmaceuticals-presented-results-from-phase-3-trial-of-mitapivat-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/agios-pharmaceuticals-presented-results-from-phase-3-trial-of-mitapivat-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4008","UP","AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643214734","title":"Agios says Phase 3 RISE UP trial shows mitapivat boosts hemoglobin response in sickle cell disease patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2643214734","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643214734?lang=en_us&edition=fundamental","pubTime":"2026-06-13 21:00","pubTimestamp":1781355626,"startTime":"0","endTime":"0","summary":"Agios presented detailed 52-week, double-blind Phase 3 RISE UP results for mitapivat in sickle cell disease at EHA 2026.The trial showed a clear improvement in anemia versus placebo, supporting mitapivat’s anti-hemolytic profile with rapid, durable effects.New analyses indicated fewer patients needed transfusions on mitapivat, with lower overall transfusion use than placebo.Patients who achieved a hemoglobin response reported meaningful benefits in pain crises, fatigue, and broader quality-of-life measures versus non-responders.Safety was broadly comparable to placebo, reinforcing a tolerability profile consistent with prior sickle cell studies.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260613:nNDL2dvfXc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","IE00BN0W2T93.GBP","BK4585","AGIO","IE00B64PRP62.GBP","LU2095319765.USD","IE00BGHQF748.EUR","BK4139","BK4112","IE00BKPKM429.USD","IE00BN0W2V16.EUR","LU2210150020.SGD","BK4588","SG9999014039.USD","LU2210149790.SGD","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","SG9999014021.USD","SG9999014013.SGD","LU0314104364.USD","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643142202","title":"Agios Showcases Rise up Phase 3 Results at Eha 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2643142202","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643142202?lang=en_us&edition=fundamental","pubTime":"2026-06-13 21:00","pubTimestamp":1781355600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260613:nTUAYMGCP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642238845","title":"Agios Pharmaceuticals Is Maintained at Neutral by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2642238845","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642238845?lang=en_us&edition=fundamental","pubTime":"2026-06-11 22:35","pubTimestamp":1781188500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AGIO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 11, 2026 10:35 ET (14:35 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642402160","title":"U.S. RESEARCH ROUNDUP-Arthur J. Gallagher & Co, Datadog, Oracle","url":"https://stock-news.laohu8.com/highlight/detail?id=2642402160","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642402160?lang=en_us&edition=fundamental","pubTime":"2026-06-11 15:59","pubTimestamp":1781164792,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Arthur J. Gallagher & Co, Datadog, Oracle June 11 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nL4N42J0KA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INCY","AMDG","HUMA","ORCS","CITR","GNRC","WMS","HNGE","BKH","INSM","CPT","HIG","AMDW","HSIC","INTC","NVST","AGIO","AMD","AMDD","KBAB","EXTR","ORCL","ASO","DDOG","CTBI","FSLR","AXSM","GEVX","NETG","EQH","CASY","AMAT","CGEM","NRGV","FE","BBYY","GKOS","CLOV","AMDY","CTVA","GEV","AJG","CHWY","CRBG","DMRA","NET","BABA","BABO","GD","ORCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642747714","title":"Agios Pharmaceuticals price target lowered to $31 from $36 at JPMorgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2642747714","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642747714?lang=en_us&edition=fundamental","pubTime":"2026-06-11 07:45","pubTimestamp":1781135110,"startTime":"0","endTime":"0","summary":"JPMorgan lowered the firm’s price target on Agios Pharmaceuticals (AGIO) to $31 from $36 and keeps a Neutral rating on the shares. The past few mon...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/agios-pharmaceuticals-price-target-lowered-to-31-from-36-at-jpmorgan-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/agios-pharmaceuticals-price-target-lowered-to-31-from-36-at-jpmorgan-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PGF","AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642144474","title":"Analysts Are Neutral on Top Healthcare Stocks: Stevanato Group (STVN), Agios Pharma (AGIO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2642144474","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642144474?lang=en_us&edition=fundamental","pubTime":"2026-06-11 07:30","pubTimestamp":1781134210,"startTime":"0","endTime":"0","summary":"Analysts fell to the sidelines weighing in on Stevanato Group (STVN) and Agios Pharma (AGIO) with neutral ratings, indicating that the experts are ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-neutral-on-top-healthcare-stocks-stevanato-group-stvn-agios-pharma-agio-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-neutral-on-top-healthcare-stocks-stevanato-group-stvn-agios-pharma-agio-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["STVN","XLV","AGIO","HCSG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640953136","title":"Agios Pharmaceuticals, Oscotec Sign Global Licensing Agreement for Cevidoplenib","url":"https://stock-news.laohu8.com/highlight/detail?id=2640953136","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640953136?lang=en_us&edition=fundamental","pubTime":"2026-06-01 18:31","pubTimestamp":1780309879,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals  secured exclusive global rights from Oscotec to develop and commercialize cevidoplenib, a next-generation oral SYK inhibitor for immune thrombocytopenia, the company said Monday.Under the agreement, Agios obtained worldwide development and commercialization rights to cevidoplenib and plans to advance the candidate into a Phase III trial in ITP in the first half of 2028.Oscotec will receive a $25 million upfront payment and could earn up to $140 million in development and regulatory milestone payments, in addition to commercial milestones and tiered royalties on future sales, the company said.Agios said the deal expands its rare hematology portfolio into ITP and could support up to $1 billion in peak annual US sales.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AGIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640293070","title":"Agios posts investor deck on cevidoplenib licensing deal in immune thrombocytopenia (ITP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640293070","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640293070?lang=en_us&edition=fundamental","pubTime":"2026-06-01 17:56","pubTimestamp":1780307775,"startTime":"0","endTime":"0","summary":"Agios licensed cevidoplenib, a next-generation SYK inhibitor, expanding into immune thrombocytopenia, an estimated $3 billion-plus global market by 2030.Deal terms include a USD 25 million upfront payment, up to USD 140 million in development and regulatory milestones, tiered royalties from high single digits to mid-teens.Management pegged the U.S. commercial opportunity at up to USD 1 billion in peak annual sales, targeting about 24,000 refractory patients.Phase 2 met a key durability endpoint: 50% achieved at least two consecutive platelet counts ≥30,000/L vs 8.3% on placebo .Phase 3 is planned for the first half of 2028, with FY 2026 OpEx expected to be roughly flat vs FY 2025 excluding the upfront payment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investm","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL4yq7C4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AGIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640374029","title":"Agios Pharmaceuticals enters license pact with Oscotec to develop cevidoplenib","url":"https://stock-news.laohu8.com/highlight/detail?id=2640374029","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640374029?lang=en_us&edition=fundamental","pubTime":"2026-06-01 17:13","pubTimestamp":1780305215,"startTime":"0","endTime":"0","summary":"Agios Pharmaceuticals (AGIO) announced an agreement with Oscotec, headquartered in South Korea, to license the exclusive global rights to cevidople...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/agios-pharmaceuticals-enters-license-pact-with-oscotec-to-develop-cevidoplenib-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/agios-pharmaceuticals-enters-license-pact-with-oscotec-to-develop-cevidoplenib-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AGIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640293788","title":"Agios licenses exclusive global rights from Oscotec to SYK inhibitor cevidoplenib in deal with USD 25 million upfront payment","url":"https://stock-news.laohu8.com/highlight/detail?id=2640293788","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640293788?lang=en_us&edition=fundamental","pubTime":"2026-06-01 17:01","pubTimestamp":1780304464,"startTime":"0","endTime":"0","summary":"Agios licenses exclusive global rights from Oscotec to SYK inhibitor cevidoplenib in deal with USD 25 million upfront payment. Agios signed an exclusive global license deal with Oscotec for cevidoplenib, a late-stage oral SYK inhibitor.Deal adds an immune thrombocytopenia program; Agios targets up to USD 1 billion in peak U.S. sales potential.Oscotec gets USD 25 million upfront; eligible for up to USD 140 million in development and regulatory milestones.Agreement includes commercial milestones; tiered royalties from high single digits to mid-teens on net sales.Oscotec can seek exclusive South Korea rights after Phase 3 results; Agios plans Phase 3 start in H1 2028.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL7tvzsX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00B3QW5Z07.USD","SG9999014021.USD","BK4139","SG9999014005.SGD","SG9999014039.USD","LU2210149790.SGD","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","NDAQ","AGIO","LU2210150020.SGD","BK4112","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","LU2095319765.USD","SG9999014013.SGD","BK4588","BK4585","IE00BKPKM429.USD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640932709","title":"Agios Pharmaceuticals - Oscotec to Receive $25 Mln Upfront Plus Milestone Payments and Tiered Royalties","url":"https://stock-news.laohu8.com/highlight/detail?id=2640932709","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640932709?lang=en_us&edition=fundamental","pubTime":"2026-06-01 17:00","pubTimestamp":1780304400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nTUA728G4N:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AGIO"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.agios.com","stockEarnings":[{"period":"1week","weight":0.1095},{"period":"1month","weight":0.3242},{"period":"3month","weight":0.2878},{"period":"6month","weight":0.3526},{"period":"1year","weight":0.1263},{"period":"ytd","weight":0.3924}],"compareEarnings":[{"period":"1week","weight":-0.0238},{"period":"1month","weight":-0.0286},{"period":"3month","weight":0.1497},{"period":"6month","weight":0.056},{"period":"1year","weight":0.1914},{"period":"ytd","weight":0.069}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.846154,"avgChangeRate":0.040392},{"month":2,"riseRate":0.692308,"avgChangeRate":0.060535},{"month":3,"riseRate":0.538462,"avgChangeRate":-0.001595},{"month":4,"riseRate":0.538462,"avgChangeRate":-0.007034},{"month":5,"riseRate":0.615385,"avgChangeRate":0.052079},{"month":6,"riseRate":0.692308,"avgChangeRate":0.064549},{"month":7,"riseRate":0.416667,"avgChangeRate":-0.012275},{"month":8,"riseRate":0.384615,"avgChangeRate":-0.041451},{"month":9,"riseRate":0.538462,"avgChangeRate":0.042929},{"month":10,"riseRate":0.384615,"avgChangeRate":-0.007074},{"month":11,"riseRate":0.615385,"avgChangeRate":0.033339},{"month":12,"riseRate":0.384615,"avgChangeRate":-0.051358}],"exchange":"NASDAQ","name":"Agios Pharmaceuticals","nameEN":"Agios Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Agios Pharmaceuticals(AGIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Agios Pharmaceuticals(AGIO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Agios Pharmaceuticals,AGIO,Agios Pharmaceuticals股票,Agios Pharmaceuticals股票老虎,Agios Pharmaceuticals股票老虎国际,Agios Pharmaceuticals行情,Agios Pharmaceuticals股票行情,Agios Pharmaceuticals股价,Agios Pharmaceuticals股市,Agios Pharmaceuticals股票价格,Agios Pharmaceuticals股票交易,Agios Pharmaceuticals股票购买,Agios Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Agios Pharmaceuticals(AGIO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Agios Pharmaceuticals(AGIO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}